Research Article
Prognostic Impact of Prephase Treatment Prior to First-Line Treatment in DLBCL: A Population-Based Registry Study
Table 1
Patient and tumour characteristics at diagnosis of diffuse large B-cell lymphoma.
| | All patients (N = 340) | Before propensity score matching | After propensity score matching | | With prephase (N = 126) | Without prephase (N = 214) | | With prephase (N = 97) | Without prephase (N = 97) | |
| | Age (median (min-max)), years | 65 [18–80] | 67 [20–80] | 65 [18–80] | 0.06 | 67 [20–80] | 67 [19–80] | 1.00 | | Sex ratio (male/female) | 1.5 (204/136) | 1.7 (80/46) | 1.4 (124/90) | 0.31 | 1.7 (61/36) | 1.7 (61/36) | 1.00 | | Stage | | | | 0.0005 | | | 0.86 | | I-II | 91 (27%) | 20 (16%) | 71 (33%) | | 19 (20%) | 20 (21%) | | | III-IV | 249 (73%) | 106 (84%) | 143 (67%) | | 78 (80%) | 77 (79%) | | | Stage B | 127 (37%) | 65 (52%) | 62 (29%) | <0.0001 | 44 (45%) | 41 (42%) | 0.66 | | Bulky (X) | 138 (40%) | 67 (53%) | 71 (33%) | 0.0003 | 50 (52%) | 50 (52%) | 1.00 | | Serum LDH > normal | 200 (60%) | 92 (75%) | 108 (52%) | <0.0001 | 68 (70%) | 65 (67%) | 0.64 | | PS | | | | <0.0001 | | | 0.44 | | 0-1 | 251 (74%) | 66 (52%) | 185 (86%) | | 64 (66%) | 69 (71%) | | | >1 | 89 (26%) | 60 (48%) | 29 (14%) | | 33 (34%) | 28 (29%) | | | aaIPI score | | | | <0.0001 | | | 0.53 | | 0 | 60 (18%) | 10 (8%) | 50 (24%) | | 10 (10%) | 10 (10%) | | | 1 | 82 (25%) | 19 (16%) | 63 (30%) | | 19 (20%) | 25 (26%) | | | 2 | 123 (37%) | 48 (39%) | 75 (36%) | | 44 (45%) | 41 (42%) | | | 3 | 67 (20%) | 46 (37%) | 21 (10%) | | 24 (25%) | 21 (22%) | | | Place of care | | | | 0.048 | | | 0.64 | | University hospitals | 223 (66%) | 91 (72%) | 132 (62%) | | 66 (68%) | 69 (71%) | | | Hospital centers | 117 (34%) | 35 (28%) | 82 (38%) | | 31 (32%) | 28 (29%) | |
|
|
LDH, lactate dehydrogenase; PS, performance status; aaIPI, age-adjusted International Prognostic Index.
|
